Table 2 Physical performance measures at baseline, three, six, and twelve months of follow-up in patients treated with whole-body vibration and teriparatide (intervention) compared to teriparatide alone (control)

SPPB, point

Mean ± sd

Mean ± sd

Baseline

9.13 ± 1.96 n = 16

10.16 ± 1.82 n = 18

Three months

10.35 ± 1.69 n = 14

0. 014*

10.17 ± 2.00 n = 18

Six months

9.46 ± 2.29 n = 15

0.128

10.17 ± 1.70 n = 17

Twelve months

9.57 ± 2.50 n = 14

0.043*

10.24 ± 1.82 n = 17

 Baseline

18.9 ± 7.9 n = 16

13.8 ± 4.6 n = 18

 Three months

14.4 ± 6.9 n = 14

0.036*

13.0 ± 3.5 n = 18

 Six months

16.2 ± 6.3 n = 15

0.085

13.4 ± 3.7 n = 17

 Twelve months

15.7 ± 9.8 n = 14

0.040*

15.3 ± 6.6 n = 17

 Baseline

2.9 ± 0.7 n = 17

2.8 ± 0.9 n = 18

  Three months

2.7 ± 0.5 n = 15

0.722

2.8 ± 0.8 n = 18

 Six months

3.0 ± 1.0 n = 15

0.977

2.8 ± 0.9 n = 17

 Twelve months

3.4 ± 1.8 n = 15

0.049*

2.7 ± 0.8 n = 17

 Baseline

27.8 ± 4.6 n = 17

28.8 ± 2.8 n = 18

 Three months

28.3 ± 2.5 n = 15

0.525

28.4 ± 3.0 n = 18

 Six months

28.8 ± 2.4 n = 15

0.400

27.7 ± 3.1 n = 17

 Twelve months

28.9 ± 2.3 n = 15

0.191

28.3 ± 2.9 n = 17

 Baseline

10.7 ± 3.2 n = 17

9.6 ± 3.1 n = 18

 Three months

9.2 ± 2.5 n = 15

0.257

9.2 ± 2.8 n = 18

 Six months

10.0 ± 4.3 n = 15

0.395

9.3 ± 4.3 n = 17

 Twelve months

11.4 ± 7.2 n = 15

0.394

8.95 ± 2.9 n = 17

 Baseline

0.91 ± 0.37 n = 17

1.10 ± 0.43 n = 18

 Three months

1.07 ± 0.42 n = 15

0.175

1.24 ± 0.48 n = 18

 Six months

1.13 ± 0.50 n = 15

0.010*

1.27 ± 0.64 n = 17

 Twelve months

1.08 ± 0.49 n = 15

0.044*

1.36 ± 0.53 n = 17

 Baseline

38.53 ± 6.56 n = 17

37.04 ± 3.88 n = 18

 Twelve months

38.20 ± 6.65 n = 15

0.281

37.04 ± 4.84 n = 17

 Baseline

5.89 ± 0.76 n = 17

6.10 ± 0.89 n = 18

 Twelve months

5.84 ± 0.66 n = 15

0.421

6.13 ± 0.92 n = 17